Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd (NQ: ENLV )

1.020 +0.090 (+9.68%)
Streaming Delayed Price Updated: 11:50 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enlivex Therapeutics Ltd

< Previous 1 2 3 4 5 Next >
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
From Enlivex Therapeutics Ltd
Via GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via TheNewswire.com
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
By Rachael Green, Benzinga 
Via News Direct
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
From Enlivex Therapeutics Ltd
Via GlobeNewswire
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
By Rachael Green, Benzinga 
Via News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... 
Via TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM. 
Via TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
By Rachael Green, Benzinga 
Via News Direct
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an  Investigational New Drug (IND) application to study Allocetra™ in patients with... 
Via Benzinga
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
From Enlivex Therapeutics Ltd
Via GlobeNewswire
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose 
Via Benzinga
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment
Enlivex Therapeutics Ltd. 
Via Benzinga
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
Sign up for this week’s All Access giveaway here! 
Via Benzinga
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
From Enlivex Therapeutics Ltd
Via GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients. 
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds. 
Via Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera 
Via Benzinga
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
From Enlivex Therapeutics Ltd
Via GlobeNewswire
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and... 
Via Benzinga
Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That
One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms. 
Via Benzinga
Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders
Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022. 
Via Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic. 
Via Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Should Biotech Be On The Critical List?
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation. 
Via Talk Markets
51 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into... 
Via Benzinga
World Markets News For Thursday
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.